Clinical Trials Logo

Tenosynovial Giant Cell Tumor clinical trials

View clinical trials related to Tenosynovial Giant Cell Tumor.

Filter by:

NCT ID: NCT05804045 Active, not recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

Start date: April 27, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in patients with Tenosynovial Giant Cell Tumor (TGCT). The main questions it aims to answer are: - Whether the Pimicotinib(ABSK021) works well in patients with TGCT. - Whether the Pimicotinib(ABSK021) is safe in patients with TGCT. Participants will be asked to complete the study procedures: - Receive the administration of Pimicotinib(ABSK021) or placebo (a placebo is a look-alike substance that contains no active drug) about 24 weeks in study part 1. - Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2. - Receive the administration of Pimicotinib(ABSK021) till study end in study part 3. - Complete the study procedures speficied in the protocol, which is guided by researchers.

NCT ID: NCT05349643 Recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT

Start date: January 26, 2023
Phase: Phase 2
Study type: Interventional

AMB-051-07 is an Open-Label, Adaptive, Dose-Ranging Study with Long-Term Extension which will enroll approximately 48 adult subjects with TGCT for IA doses over a 24-week dosing period (Part 1) with a Part 2 OLE of 6 treatment and/or observational cycles of 12 weeks each followed by 12 weeks of follow-up.

NCT ID: NCT05059262 Active, not recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

MOTION
Start date: October 14, 2021
Phase: Phase 3
Study type: Interventional

This is a multicenter Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the tumor is not an option. The study consists of two parts. In Part 1, eligible study participants will be assigned to receive either vimseltinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Participants assigned to placebo in Part 1 will have the option to receive vimseltinib for Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label vimseltinib.

NCT ID: NCT04938180 Terminated - Clinical trials for Tenosynovial Giant Cell Tumor

A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients

Start date: September 16, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this Phase 2, open-label, multiple-dose, dose-escalation study is to evaluate intravenous AMB-05X in the treatment of subjects with TGCT.

NCT ID: NCT04731675 Active, not recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee

Start date: May 25, 2021
Phase: Phase 2
Study type: Interventional

AMB-051-01 is a multicenter study with an adaptive design that will enroll approximately 12 subjects with TGCT of the knee for 12 weeks of multiple-dose, open-label treatment with AMB-05X.

NCT ID: NCT04703322 Recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

Start date: March 15, 2021
Phase: Phase 2
Study type: Interventional

This phase 2, multicenter, two-part, open-label, single-arm study will be conducted in Japan and will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of pexidartinib in adult participants with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitation and not amenable to improvement with surgery.

NCT ID: NCT04635111 Recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

Start date: January 7, 2021
Phase:
Study type: Observational [Patient Registry]

A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) and experience hepatotoxicity.

NCT ID: NCT04526704 Completed - Clinical trials for Tenosynovial Giant Cell Tumor

Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

PLX3397
Start date: October 20, 2020
Phase: Phase 4
Study type: Interventional

This study is designed to evaluate the discontinuation/re-treatment of pexidartinib therapy in previously treated participants with tenosynovial giant cell tumor (TGCT).

NCT ID: NCT04488822 Active, not recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT

PLX3397
Start date: September 25, 2020
Phase: Phase 3
Study type: Interventional

This study will assess pexidartinib in adult participants with symptomatic TGCT that is associated with severe morbidity or functional limitations and not amendable to improvement with surgery.

NCT ID: NCT04192344 Recruiting - Neoplasms Clinical Trials

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

Start date: January 20, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.